The DOI matches its Crossref record.
FTY720: ALTERED LYMPHOCYTE TRAFFIC RESULTS IN ALLOGRAFT PROTECTION
Abstract
Current standard drugs used to prevent organ graft rejection all interfere with discrete sites in the T-cell/B-cell activation cascade. They can be classified as inhibitors of cytokine transcription (CsA, FK506), inhibitors of nucleotide synthesis (azathioprine, mycophenolate mofetil, mizoribine, leflunomide), inhibitors of growth factor signal transduction (rapamycin, leflunomide), and inhibitors of differentiation (15-deoxyspergualin) (1). The beneficial effects of these therapeutics in disease relate to their broad immunosuppressive potential; however, generalized immunosuppression may reduce defense against infection and malignancies. As described below, the novel immunomodulator FTY720 protects allografts including islets with remarkable potency, apparently without inducing generalized immunosuppression (2,3). FTY720 is a structural analog of myriocin (Fig. 1), a metabolite of the ascomycete Isaria sinclairii(4–7). However, unlike myriocin, FTY720 does not bind the serine-palmitoyl transferase and does not inhibit the sphingolipid pathway (8). Although much research has yet to be done to completely unravel the mechanism of action of FTY720, recent data suggest that the drug acts as an agonist and increases the intrinsic mobility of lymphocytes, thereby accelerating chemokine-dependent lymphocyte homing to secondary lymphoid tissues (9) and reducing the recruitment of effector lymphocytes into grafted organs and peripheral lesions (10,11). The high efficacy of the drug in animal models (3) combined with the good tolerability in Phase I and II clinical trials (12–14) may relate to the compound’s novel mode of action that has not been observed with any other immunosuppressive agent. Figure 1: Structure of FTY720.MODELS OF SOLID ORGAN TRANSPLANTATION FTY720 prolonged with remarkable potency the survival of allografted rat skin (10,15,16), heart (17,18), liver (19–23), and small bowel (20,24) in strain combinations both incompatible and compatible for the major histocompatibility complex. A dose-dependent linear increase of drug efficacy was observed over a range of 0.1 to 10 mg/kg (16). In rats, a short 2-day pretransplant treatment with FTY720 at 5 mg/kg significantly prolonged survival of liver and heart allografts (19,25), suggesting that administration of “loading” doses before transplant surgery could be beneficial. In the same models, FTY720 given only on days 3 and 4 after grafting also prolonged survival (19,26), suggesting that the drug may have potential to reverse ongoing rejection. In combination with subtherapeutic amounts of CsA, the daily dose of FTY720 could be reduced to 0.1–0.5 mg/kg to protect allografted rat skin (15) and heart (17,20), dog kidney (19,27), and monkey kidney (28) (Table 1). Comparable effects have been observed for combinations of FTY720 with rapamycin (29), RAD (30,31), and FK506 (32,33), indicating that FTY720 synergizes effectively with inhibitors of T-cell activation and proliferation to prevent acute rejection. Table 1: Prolongation of allograft survival by FTY720 alone or in combination with CsAIn transplant patients, only 2%–3% of all allografts are lost during the first year to irreversible acute rejection, whereas a larger number is lost during each subsequent year to chronic rejection (34,35). The major manifestation of chronic rejection in all organs is persistent perivascular inflammation and allograft arteriosclerosis, also termed graft-vessel disease (GVD), which is only partially controlled by classic immunosuppressants. There is now evidence that low doses of FTY720 at 0.1 mg/kg added to a subtherapeutic CsA regimen effectively suppressed all aspects of GVD in a rat carotid artery transplant model, including perivascular inflammation, concentric neointima formation, medial thinning, and necrosis (36), suggesting that this regimen could be used clinically to prevent the development of GVD. MODELS OF AUTOIMMUNE DIABETES AND ISLET TRANSPLANTATION Type 1 diabetes (or insulin dependent diabetes mellitus, and II IDDM) is a common endocrine disease caused by the progressive, autoimmune destruction of the insulin-producing β-cells within the islets of the pancreas (37). At present, daily insulin injections remain the treatment of choice for the majority of diabetic patients. Although insulin therapy sustains a good quality of life, it requires constant monitoring of glucose levels; moreover, it can delay but not prevent secondary complications. Recently, with refinement of immunosuppression and transplantation techniques, single allogeneic pancreatic or simultaneous pancreaticorenal transplantation has become a possibility, in particular for patients with chronic renal failure (38). FTY720 may be an attractive therapeutic in islet transplantation, because the drug effectively protected islet allografts in streptozotocin (STZ)-induced diabetic rats (39) and mice (40), resulting in reversal of hyperglycemia and maintenance of normoglycemia throughout treatment of >
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Self-citationLysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
Sanna, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M.-Y., Peterson, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311743200 · Cited by 626
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 581
Metadata
- Authors
- Brinkmann, V., Pinschewer, D. D., Feng, L., & Chen, S.
- Venue
- Transplantation
- Published
- 2001-09
- Volume
- 72
- Issue
- 5
- Pages
- 764-769
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2032720657
- Cited by
- 169
- References
- 0
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FTY720: ALTERED LYMPHOCYTE TRAFFIC RESULTS IN ALLOGRAFT PROTECTION. https://app.cochat.ai/papers/10.1097/00007890-200109150-00002
- The paper
- Brinkmann, V., Pinschewer, D. D., Feng, L., & Chen, S. (2001). FTY720: ALTERED LYMPHOCYTE TRAFFIC RESULTS IN ALLOGRAFT PROTECTION. Transplantation. https://doi.org/10.1097/00007890-200109150-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.